BioMarin Bets On Intracerebral Delivery To Avoid Blood-Brain Barrier
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BioMarin has seen few infusion-associated reactions from intracerebral ventricular delivery of enzyme replacement therapy for central nervous system-predominant disorders.